CN1812985A - 治疗肥胖症的mch拮抗剂 - Google Patents

治疗肥胖症的mch拮抗剂 Download PDF

Info

Publication number
CN1812985A
CN1812985A CNA2004800183172A CN200480018317A CN1812985A CN 1812985 A CN1812985 A CN 1812985A CN A2004800183172 A CNA2004800183172 A CN A2004800183172A CN 200480018317 A CN200480018317 A CN 200480018317A CN 1812985 A CN1812985 A CN 1812985A
Authority
CN
China
Prior art keywords
compound
alkyl
aryl
substituted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800183172A
Other languages
English (en)
Chinese (zh)
Inventor
A·帕拉尼
S·A·夏皮罗
H·B·若西恩
T·A·巴拉
J·W·克拉德
P·B·普什帕瓦纳姆
S·李
M·麦布里尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1812985A publication Critical patent/CN1812985A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2004800183172A 2003-06-30 2004-06-28 治疗肥胖症的mch拮抗剂 Pending CN1812985A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48361903P 2003-06-30 2003-06-30
US60/483,619 2003-06-30

Publications (1)

Publication Number Publication Date
CN1812985A true CN1812985A (zh) 2006-08-02

Family

ID=34061963

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800183172A Pending CN1812985A (zh) 2003-06-30 2004-06-28 治疗肥胖症的mch拮抗剂

Country Status (7)

Country Link
US (1) US7345042B2 (enExample)
EP (1) EP1644366A1 (enExample)
JP (1) JP4605801B2 (enExample)
CN (1) CN1812985A (enExample)
CA (1) CA2526725A1 (enExample)
MX (1) MXPA05013596A (enExample)
WO (1) WO2005005419A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2562235C (en) 2004-04-13 2013-09-24 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
CN117100751A (zh) 2017-06-20 2023-11-24 安布里亚制药公司 用于提高心脏代谢效率的组合物和方法
EP3866794B1 (en) 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
DE60021370C5 (de) 1999-05-04 2007-11-08 Schering Corp. Piperazinderivate verwendbar als ccr5 antagonisten
CA2414198A1 (en) * 2000-07-06 2002-01-17 Neurogen Corporation Melanin concentrating hormone receptor ligands
US6900329B2 (en) * 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
EP1389189A2 (en) * 2001-05-22 2004-02-18 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
WO2003045918A1 (en) * 2001-11-26 2003-06-05 Schering Corporation Piperidine-based mch antagonists for treatment of obesity and cns disorders
EP1465888A2 (en) * 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
WO2004078717A1 (en) * 2003-03-03 2004-09-16 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
CA2529161A1 (en) * 2003-06-13 2004-12-29 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists

Also Published As

Publication number Publication date
JP4605801B2 (ja) 2011-01-05
WO2005005419A1 (en) 2005-01-20
CA2526725A1 (en) 2005-01-20
US20050004121A1 (en) 2005-01-06
MXPA05013596A (es) 2006-03-09
EP1644366A1 (en) 2006-04-12
JP2007521286A (ja) 2007-08-02
US7345042B2 (en) 2008-03-18

Similar Documents

Publication Publication Date Title
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1990471A (zh) Mch拮抗剂及其在治疗肥胖症方面的用途
CN1246319C (zh) 氨基(硫)醚衍生物
CN1761646A (zh) 大麻素受体配位体
CN1585749A (zh) 类大麻苷受体配体
CN1592739A (zh) 用于治疗肥胖和cns疾病的基于哌啶的mch拮抗剂
CN1575169A (zh) 用于治疗肥胖的mch拮抗剂
CN1305862C (zh) 作为腺苷受体配体的7－氨基苯并噻唑衍生物
CN1498205A (zh) 具有mch调节活性的芳基和二芳基化合物
CN1678317A (zh) 用作治疗呕吐、抑郁症、焦虑症和咳嗽的神经激肽－1(nk－1)拮抗剂的1－酰氨基－4－苯基－4－苄氧基甲基－哌啶衍生物和相关化合物
CN1474810A (zh) 取代脲,神经肽yy5受体拮抗剂
CN1558764A (zh) 取代脲类神经肽yy5受体拮抗剂
CN1426411A (zh) 3－(二芳基亚甲基)－8－氮杂双环[3.2.1]辛烷衍生物
CN1143848C (zh) 用作毒蕈碱性受体拮抗剂的2-芳基乙基-(哌啶-4-基甲基)胺衍生物
CN1662496A (zh) 大麻素受体激动剂
CN1596258A (zh) 腺A2α受体拮抗剂
HK1044337A1 (en) Amide compounds
CN1649845A (zh) 蝇蕈碱拮抗剂
CN1890208A (zh) 类鸦片受体拮抗剂
CN101076524A (zh) 作为选择性黑色素浓集激素受体拮抗剂的治疗肥胖和相关病症的双环化合物
CN1617718A (zh) 用于治疗肥胖症的作为mch拮抗剂的n－芳基－n′－芳基环烷基脲衍生物
CN1032438A (zh) 新的取代的n-(1-烷基-3-羟基-4-哌啶基)苯甲酰胺
CN1678608A (zh) 新的神经肽yy5受体拮抗剂
CN1478092A (zh) 苯并噁嗪酮衍生物及其制备和应用
CN1665812A (zh) 用于治疗肥胖的作为选择性黑色素浓缩激素受体拮抗剂的螺取代的哌啶化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication